Skip to NavigationSkip to content

News

0
Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, it has...
0
Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, and diagnostics.
0
Celgene has revealed the US approval of Otezla for the treatment of with oral ulcers in adult patients with the rare and chronic inflammatory...
0
The Department of Health and Social Care (DHSC) paid £9.2 billion to private providers in the year prior to 31 March 2019, according to their annual...

Features

The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the quality of generics has been sacrificed in the...